Price & Reimbursement: Contributed strategic inputs and analyses to support the Ministry of Health reimbursement process for Amvutra-CM, ensuring Spain is positioned for a timely decision 4 months ahead of launch. • Market Access: Designed a national and regional access acceleration plan, mapping influence pathways, pharmacy commitees, and activation timelines across priority hospitals • Launch Strategy: Built the overarching Spain launch strategy Market Access, Medical , Commercial for Amvutra-CM, aligning patient segmentation, access priorities, tactical sequencing, and performance milestones. Delivered the 2026 Brand Plan and Tactical Plan. • Go-to-Market Model: Adjusted the field execution model to transition from a rare-disease footprint to a scalable specialty-care approach for cardiology. • Account Activation: Created a comprehensive hospital and territory mapping framework with weekly KAM review processes to identify early adopters and accelerate account readiness. • Team Business Acumen: Assessed commercial and cross-functional capabilities to strengthen decision- making, business planning, and field execution. • Team Training & Competency Development: Launched structured coaching and capability-building eforts aligned with the competencies needed for a cardiology specialty-care launch. • Launch Readiness Plan: Led the end-to-end design of the Amvutra-CM Launch Readiness Deep Dive, presenting Spain’s strategy, access plan, forecast, success metrics, and activation roadmap to EVP Region EU and international leadership. • KOL Engagement: Established rapid, high-quality engagement with national and regional KOLs through congress participation, workshops, and direct discussions, strengthening clinical advocacy ahead of launch. • Governance & Operating Rhythm Creation: Established the launch governance framework (weekly KAM reviews, cross-functional coordination,account activation rhythm), bringing structure, predictability, and visibility to a previously unstructured launch environment.

( S wedish Orphan Biovitrum), Swiss EU HQ, Basel(CH) Hybrid, Europe based • Global Launch Strategy & Execution: Designed and executed the global launch strategy for pegcetacoplan in hematology (Paroxysmal Nocturnal Hemoglobinuria – PNH), successfully supporting the product launch in 33+ countries across EU, Japan, and LATAM, ensuring a best-in-class launch in the hematology space delivering over €100 million within 30 months. • Regulatory & Market Prioritization: Led the regulatory submission strategy and market prioritization to optimize speed to market, securing approvals and reimbursement pathways in Hemathology (NaïveIndication & ODD status maintenance) while preparing for the upcoming Nephrology indications launch (C3G / IC-MPGN) ensuring blockbuster potential. • P&L Ownership & Revenue Growth: Closed 2024 with > €100 million in sales for pegcetacoplan in hematology, leveraging strong market access strategies, pricing frameworks, and commercial excellence initiatives. Delivered a sharp 5Y-Long Range Plan guidance to guarantee continued growth over next 5 years and pipeline exansion. Worked closely with each region /affiliate to implement guidance and delivered double digit growth forecast to CEO and Board of Directors. • Pricing, Reimbursement & Market Access: Coordinated global pricing, local reimbursement, and innovative afordability strategies, ensuring optimal market penetration and sustainable patient access across diverse healthcare systems (i.e.: EU, PMDA Japan, Distributor network LATAM) • Lifecycle Management & Strategic Partnerships: Led alliance management with Apellis USA, driving KOL engagement, lifecycle strategies, data generation, publications, congress strategy, and launch preparations for new indications in C3G and IC-MPGN (ultra-rare kidney diseases) while contributing to due diligence for business development opportunities in other therapeutic areas: PNH, CAD, FSGS, ALS,DGF, MG, Lupus. • Cross-functional Leadership & Team Development: Built, led, developed a global commercial team of six direct reports and a cross functional 15-member Core Asset Team spanning clinical, medical afairs, regulatory, geographic expansion, medical devices, commercial, tech ops, supply chain, business development, alliance management , fostering collaboration, strategic alignment, and executional excellence.

Spain (presential) • Accelerated Sales Growth & Portfolio Expansion: Spearheaded the commercial (marketing, sales andmarket access) and tactical strategy for the hemophilia portfolio (Elocta® & Alprolix®), driving sales growth from €26M to €34M, optimizing promotional budget allocation, and implementing high impact sales initiatives. • Market Access & Strategic Launch Execution: Designed and executed regional market access and

Transformed Anesthesia & Reanimation Franchise: Redefined the commercial strategy for Bridion® (€50M) and LOE Esmeron® (€3M), driving 16% brand growth. Led a nationwide shift in patient safety positioning, establishing Bridion® as a critical OR standard. • Pioneered Digital & Structural Innovation: Launched ASTRIDE, a Veeva-powered digital engagement model, recognized as an international best practice. Revamped the marketing and sales leadership teams, overseeing 23 direct reports, while previously dismantling Sanofi-Pasteur-MSD and reintegrating Merck’s vaccine portfolio with a new commercial model. • Led the full integration of Sanofi Pasteur MSD ́s vaccine portfolio into MSD Spain: incorporating key assets including Gardasil®/Gardasil 9®, RotaTeq®, Hexavac®, Varivax®, Zostavax®, Pneumovax 23®, and M-M-RVAXPRO®. Coordinated with Sanofi Pasteur Spain’s General Manager, Finance, and Medical leadership to execute asset transfers, workforce transitions, long-range planning, and go-to-market strategy for both public and private vaccine markets. • Global Market Access Leadership – Keytruda®: Led a special global market access assignment across USA, Spain, Italy, and France, driving reimbursement strategies and afordability solutions to expand patient access to blockbuster oncology drug Keytruda®. Established a global alliance with GE Healthcare to accelerate lung cancer treatment pathways.

P&L & Commercial Leadership: Managed a €350M sales portfolio with a €4M promotional budget, overseeing the HIV franchise strategy and leading 60+ commercial team members across marketing and sales. • Market-Shaping HIV Launches: Strengthened the Eviplera® launch (best ARV launch in HIV, IMS 2013), successfully co-promoted Eviplera® & Edurant® with Janssen-Cilag, and led the Stribild® launch, introducing the first integrase inhibitor in STR format. • Strategic Growth & Team Expansion: Designed a co-positioning strategy for Truvada, Atripla, Eviplera & Stribild, maximizing market share. Built two specialized sales teams, recruiting 11 new reps, and c o ntributed to late-stage global development for Genvoya® (TAF transition)

Global Launch & Competitive Readiness: Led the AVONEX PEN launch across 22 countries (EU, USA,Japan), delivering strategy, training, and materials, while driving competitive readiness for the IFN franchise, preparing BIIB for key market events like the Aubagio® USA launch. • Strategic MS Portfolio Positioning: Designed the global co-positioning strategy for the Multiple Sclerosis portfolio (AVONEX®, TYSABRI®, BG12, FAMPYRA®) and contributed to the late-stage development & pre-launch strategy of Plegridy®, ensuring cross functional alignment.

TYSABRI® Growth & Strategic Excellence: Drove +15% sales growth in 2011 with a €2.5M budget, restructured the marketing mix, launched STRATIFY® nationwide, and led the TYSEM 360o initiative, strengthening KOL engagement and sales force scientific training—earning the Global Marketing Award Affiliate of the Year.

PCa | Abbott Laboratories, Spain • Strategic Patient & Stakeholder Engagement: Designed and implemented "Salud y Trabajo", collaborating with rheumatology KOL leaders to strengthen Humira®’s positioning. Launched a Patient Aid Program and Mira Magazine, enhancing patient awareness and compliance in RA & SpA. • Market Leadership & Sales Growth: Reversed Procrin®'s stagnation (-0.4%), achieving +4.7% sales growth in 2007, while maintaining a 33% market share in prostate cancer despite competition. • Adaptability & Leadership in Uro-Oncology: Successfully managed full franchise lifecycle, integrating into a mature team and building a solid long-range plan, securing a promotion to manager.